Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

Roche claimed FDA approval for Tecentriq (atezolizumab) in the US last year as an adjuvant for some NSCLC patients, and has now got a green light for this indication from the European Commission ...

The combination of Roche’s monoclonal antibody Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) was shown to help people live ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

How Is the Tecentriq Atezolizumab Market Expected to Grow? .The Tecentriq Atezolizumab market is experiencing substantial growth, projected to expand from $3,880 million in 2024 to $4,360 million ...

Tecentriq (atezolizumab) in combination with bevacizumab will help the 70 or so New Zealanders diagnosed with Hepatocellular Carcinoma (HCC) each year. Country medical director at Roche New ...

Atezolizumab, hyaluronidase-tqjs 1875mg/30000 ... In the doses administered, hyaluronidase in Tecentriq Hybreza acts transiently and locally. Severe and fatal immune-mediated adverse reactions ...

In 2023, Xilio entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq ) in a multi-center, open-label Phase 1/2 ...

Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 Technology appraisal guidance TBC Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as ...